403 related articles for article (PubMed ID: 28137302)
1. IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights.
Li H; Batth IS; Qu X; Xu L; Song N; Wang R; Liu Y
Mol Cancer; 2017 Jan; 16(1):6. PubMed ID: 28137302
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy.
Hua H; Kong Q; Yin J; Zhang J; Jiang Y
J Hematol Oncol; 2020 Jun; 13(1):64. PubMed ID: 32493414
[TBL] [Abstract][Full Text] [Related]
3. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
[TBL] [Abstract][Full Text] [Related]
4. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B; Shim JS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
[TBL] [Abstract][Full Text] [Related]
5. IGF-I Induces Epithelial-to-Mesenchymal Transition via the IGF-IR-Src-MicroRNA-30a-E-Cadherin Pathway in Nasopharyngeal Carcinoma Cells.
Wang R; Li H; Guo X; Wang Z; Liang S; Dang C
Oncol Res; 2016; 24(4):225-31. PubMed ID: 27656832
[TBL] [Abstract][Full Text] [Related]
6. The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.
Bieghs L; Johnsen HE; Maes K; Menu E; Van Valckenborgh E; Overgaard MT; Nyegaard M; Conover CA; Vanderkerken K; De Bruyne E
Oncotarget; 2016 Jul; 7(30):48732-48752. PubMed ID: 27129151
[TBL] [Abstract][Full Text] [Related]
7. The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies.
Motallebnezhad M; Aghebati-Maleki L; Jadidi-Niaragh F; Nickho H; Samadi-Kafil H; Shamsasenjan K; Yousefi M
Tumour Biol; 2016 Sep; 37(9):11711-11721. PubMed ID: 27444280
[TBL] [Abstract][Full Text] [Related]
8. The IGF2/IR/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma.
Vaquero J; Lobe C; Tahraoui S; Clapéron A; Mergey M; Merabtene F; Wendum D; Coulouarn C; Housset C; Desbois-Mouthon C; Praz F; Fouassier L
Clin Cancer Res; 2018 Sep; 24(17):4282-4296. PubMed ID: 29716918
[No Abstract] [Full Text] [Related]
9. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
[TBL] [Abstract][Full Text] [Related]
10. Activation of IGF/IGF-IR signaling pathway fails to induce epithelial-mesenchymal transition in pancreatic cancer cells.
Kopantzev EP; Kopantseva MR; Grankina EV; Mikaelyan A; Egorov VI; Sverdlov ED
Pancreatology; 2019 Mar; 19(2):390-396. PubMed ID: 30799278
[TBL] [Abstract][Full Text] [Related]
11. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
12. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
Knowlden JM; Jones HE; Barrow D; Gee JM; Nicholson RI; Hutcheson IR
Breast Cancer Res Treat; 2008 Sep; 111(1):79-91. PubMed ID: 17902048
[TBL] [Abstract][Full Text] [Related]
13. Clinical studies in humans targeting the various components of the IGF system show lack of efficacy in the treatment of cancer.
Philippou A; Christopoulos PF; Koutsilieris DM
Mutat Res Rev Mutat Res; 2017; 772():105-122. PubMed ID: 28528684
[TBL] [Abstract][Full Text] [Related]
14. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS
Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
16. Disrupting insulin-like growth factor signaling as a potential cancer therapy.
Sachdev D; Yee D
Mol Cancer Ther; 2007 Jan; 6(1):1-12. PubMed ID: 17237261
[TBL] [Abstract][Full Text] [Related]
17. Molecular Imaging of IGF-1R in Cancer.
Sun Y; Sun X; Shen B
Mol Imaging; 2017; 16():1536012117736648. PubMed ID: 29169312
[TBL] [Abstract][Full Text] [Related]
18. Minireview: Were the IGF Signaling Inhibitors All Bad?
Beckwith H; Yee D
Mol Endocrinol; 2015 Nov; 29(11):1549-57. PubMed ID: 26366975
[TBL] [Abstract][Full Text] [Related]
19. The role of epithelial-mesenchymal transition-regulating transcription factors in anti-cancer drug resistance.
Seo J; Ha J; Kang E; Cho S
Arch Pharm Res; 2021 Mar; 44(3):281-292. PubMed ID: 33768509
[TBL] [Abstract][Full Text] [Related]
20. IGF/STAT3/NANOG/Slug Signaling Axis Simultaneously Controls Epithelial-Mesenchymal Transition and Stemness Maintenance in Colorectal Cancer.
Yao C; Su L; Shan J; Zhu C; Liu L; Liu C; Xu Y; Yang Z; Bian X; Shao J; Li J; Lai M; Shen J; Qian C
Stem Cells; 2016 Apr; 34(4):820-31. PubMed ID: 26840943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
